1. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.
- Author
-
Ueberroth BE, Lieu CH, and Lentz RW
- Subjects
- Humans, Male, Middle Aged, Liver Neoplasms secondary, Liver Neoplasms drug therapy, Liver Neoplasms genetics, Female, Neoplasm Grading, Treatment Outcome, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Imidazoles therapeutic use, Imidazoles administration & dosage, Imidazoles adverse effects, Oximes therapeutic use, Oximes administration & dosage, Proto-Oncogene Proteins B-raf genetics, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology, Pyrimidinones therapeutic use, Pyrimidinones administration & dosage, Pyridones therapeutic use, Pyridones administration & dosage, Mutation, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors genetics, Neuroendocrine Tumors pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Purpose: Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3., Methods: This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue., Results: This patient has demonstrated an ongoing partial response to therapy at all involved sites for nearly 15 months with minimal side effects attributable to D/T., Conclusion: Dabrafenib/trametinib therapy for BRAF-mutated metastatic pancNETs provides a novel treatment option and, especially in the G3 setting, should be considered a first-line option. Tumor testing for actionable mutations should be undertaken at the time of diagnosis and/or progression to identify novel therapeutic avenues in these rare tumors., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF